-
Statement /
-
Featured News /Novartis transforms its Global Health & Corporate Responsibility organization.
-
Featured News /
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. -
Story /Ambitious scientist accelerates research into African genomic diversity and health challenges with internship
-
Story /Blocking an inflammatory pathway may offer a new way to treat autoimmune disease.
-
Story /Learn how Novartis is using technology to improve the oncology clinical trial process.
-
Story /Novartis researchers leverage in-house startup initiative to begin digital technology research collaboration.
-
Story /Our Global Head of Patient Affairs and Policy shares why it’s critical to engage patients throughout the drug development process.
-
Story /Meet our Vice President of Strategic Data and Digital at Novartis Oncology.
-
Story /Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.